METROCREAM - CRM 0.75%

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

METRONIDAZOLE

から入手可能:

GALDERMA CANADA INC

ATCコード:

D06BX01

INN（国際名）:

METRONIDAZOLE

投薬量:

.75%

医薬品形態:

CREAM

構図:

METRONIDAZOLE .75%

投与経路:

TOPICAL

パッケージ内のユニット:

3/60G

処方タイプ:

Prescription

治療領域:

ANTIBIOTICS

製品概要:

Active ingredient group (AIG) number: 0102572005; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2017-08-01

製品の特徴

_ _
_METROGEL 0.75% and 1%, METROCREAM, METROLOTION Page 1 of 24_
PRODUCT MONOGRAPH
PR
METROGEL

metronidazole topical gel USP, 0.75%
metronidazole topical gel
Galderma Std
, 1%
PR
METROCREAM

metronidazole topical cream, 0.75%
PR
METROLOTION™
metronidazole topical lotion, 0.75%
FOR TOPICAL USE ONLY
(NOT FOR OPHTHALMIC USE)
Anti-Rosacea Agent
D06BX01
GALDERMA CANADA INC.
105 Commerce Valley Drive W., Suite 300
Thornhill, ON L3T 7W3
Date of Preparation:
July 17, 2007
Date of Revision:
January 7, 2014
Submission Control No: 169473
_ _
_METROGEL 0.75% and 1%, METROCREAM, METROLOTION Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................10
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
..............................................................................